Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MEI Pharma, Inc. - Common Stock (NQ: MEIP )

2.370 +0.010 (+0.42%)
Streaming Delayed Price Updated: 2:46 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MEI Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
18 Stocks Moving in Wednesday's Pre-Market Session
Gainers Endo International plc (NASDAQ: ENDP) rose 46.1% to $0.7710 in pre-market trading after gaining over 12% on Tuesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
From MEI Pharma, Inc.
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Encourages MEI Pharma, Inc. Investors with Losses to Inquire About Class Action Investigation – MEIP
From Rosen Law Firm
Via Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
Analyzing Mei Pharma Inc's Short Interest
Mei Pharma Inc's (NASDAQ:MEIP) short percent of float has risen 10.86% since its last report. The company recently reported that it has 7.31 million shares sold short, which is 6.... 
Via Benzinga
64 Biggest Movers From Friday
Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) shares surged 143% to settle at $3.84 on Friday after the company reported better-than-expected Q4 sales results and reaffirmed... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Expert Ratings For MEI Pharma
Analysts have provided the following ratings for MEI Pharma (NASDAQ:MEIP) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Mid-Afternoon Market Update: Dow Falls 30 Points; Cutera Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 100 points on Friday. The Dow traded down 0.09% to 34,677.25 while the NASDAQ fell... 
Via Benzinga
Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update
The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Mid-Day Market Update: Nasdaq Down 1%; Icosavax Shares Plummet
U.S. stocks pared gains midway through trading, with the Nasdaq Composite dropping 1% on Friday. The Dow traded up 0.02% to 34,715.99 while the NASDAQ fell 1.02% to 14,045.00... 
Via Benzinga
36 Stocks Moving In Friday's Mid-Day Session
Gainers Forge Global Holdings, Inc. (NYSE: FRGE) shares jumped 66.4% to $20.70. Clever Leaves Holdings Inc. (NASDAQ: CLVR) jumped 29.1% to $2.04 after the company reported... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.